Antonio
Oliver Palomo
Publicaciones en las que colabora con Antonio Oliver Palomo (15)
2024
-
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions
International Journal of Antimicrobial Agents, Vol. 63, Núm. 5
2023
-
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200
2022
-
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815
-
Selection of AmpC β-Lactamase Variants and Metalloβ- Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/ XDR Pseudomonas aeruginosa Infections
Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2
2021
-
6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β-Lactam Antibiotics
Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 6310-6328
2020
-
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection
The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 11, pp. 3209-3217
2019
-
Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone
Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10
-
Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii
Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10
2018
-
Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu217-218 Insertion in the Ω-Loop
Microbial Drug Resistance, Vol. 24, Núm. 5, pp. 527-533
2014
-
Genetic and kinetic characterization of the novel AmpC β-lactamases DHA-6 and DHA-7
Antimicrobial Agents and Chemotherapy, Vol. 58, Núm. 11, pp. 6544-6549
2012
-
Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate
Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 8, pp. 4540-4543
-
Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: Molecular mechanisms, penicillin-binding protein profiles, and binding affinities
Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 9, pp. 4771-4778
2011
-
Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-β-lactamases-authors' response
Journal of Antimicrobial Chemotherapy
2010
-
Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-β-lactamases
Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 9, pp. 1950-1954
2008
-
Characterization of the new metallo-β-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain
Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 10, pp. 3589-3596